Compare Davita Inc (DVA) vs MPLX LP (MPLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs MPLX LP — how do they compare? Davita Inc trades at $230.93 (market cap $14.92B), while MPLX LP trades at $56.42 (market cap $57.34B). The key difference: MPLX LP is far larger — about 3.8× Davita Inc's market cap, and MPLX LP pays a 7.62% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| DVA | MPLX | |
|---|---|---|
Market Cap | $14.92B | $57.34B |
Sector | Health | Technology |
52-Week High | $235.71 | $59.17 |
52-Week Low | $103.87 | $47.80 |
Enterprise Value | $27.47B | $81.97B |
Dividend Yield | — | 7.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
MPLX trades at $57.21, up 0.46% today, with a bullish technical outlook supported by moving averages and a consensus price target of $60.60. The company reported strong profitability with a 41.24% net income margin and robust cash flow from operations of $5.91B in 2025. Recent earnings showed beats in Q3 and Q4 2025 but a miss in Q1 2026, with Q2 2026 results pending. A dividend of $1.08 was declared for H1-26, reinforcing income appeal.
The stock presents a compelling value with a P/E of 12.23 and high analyst buy consensus (71.43%), though risks include earnings volatility and high debt-to-asset ratio of 90.06%. Upside is supported by stable midstream operations and Permian Basin exposure, but investors should monitor Q2 2026 earnings for growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →
